Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach.

Ahn KS, O'Brien D, Kang YN, Mounajjed T, Kim YH, Kim TS, Kocher JA, Allotey LK, Borad MJ, Roberts LR, Kang KJ.

Hepatol Int. 2019 Jun 18. doi: 10.1007/s12072-019-09954-3. [Epub ahead of print]

PMID:
31214875
2.

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.

Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ.

JAMA Oncol. 2019 Apr 18. doi: 10.1001/jamaoncol.2019.0270. [Epub ahead of print]

PMID:
30998813
3.

Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis.

Yadav S, Xie H, Bin-Riaz I, Sharma P, Durani U, Goyal G, Borah B, Borad MJ, Smoot RL, Roberts LR, Go RS, McWilliams RR, Mahipal A.

Eur J Surg Oncol. 2019 Mar 21. pii: S0748-7983(19)30351-8. doi: 10.1016/j.ejso.2019.03.023. [Epub ahead of print]

PMID:
30914290
4.

Hepatocytes direct the formation of a pro-metastatic niche in the liver.

Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, Delman D, Graham K, Gladney WL, Hua X, Black TA, Chien AL, Majmundar KS, Thompson JC, Yee SS, O'Hara MH, Aggarwal C, Xin D, Shaked A, Gao M, Liu D, Borad MJ, Ramanathan RK, Carpenter EL, Ji A, de Beer MC, de Beer FC, Webb NR, Beatty GL.

Nature. 2019 Mar;567(7747):249-252. doi: 10.1038/s41586-019-1004-y. Epub 2019 Mar 6.

PMID:
30842658
5.

Decline in the seroprevalence of syphilis markers among first-time blood donors in Libreville (Gabon) between 2004 and 2016.

Bisseye C, Eko Mba JM, Ntsame Ndong JM, Kosiorek HE, Butterfield RJ, Mombo LE, M'batchi B, Borad MJ, Nagalo BM, Allain JP.

BMC Public Health. 2019 Feb 8;19(1):167. doi: 10.1186/s12889-019-6489-7.

6.

Erratum: Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum].

Babiker HM, Riaz IB, Husnain M, Borad MJ.

Oncolytic Virother. 2019 Jan 4;8:1. doi: 10.2147/OV.S196145. eCollection 2019.

7.

Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience.

DeLeon TT, Salomao MA, Aqel BA, Sonbol MB, Yokoda RT, Ali AH, Moss AA, Mathur AK, Chascsa DM, Rakela J, Bryce AH, Borad MJ.

J Gastrointest Oncol. 2018 Dec;9(6):1054-1062. doi: 10.21037/jgo.2018.07.05.

8.

Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma.

Zakharia K, Miyabe K, Wang Y, Wu D, Moser CD, Borad MJ, Roberts LR.

Transl Oncol. 2019 Jan;12(1):143-153. doi: 10.1016/j.tranon.2018.09.005. Epub 2018 Oct 11.

9.

Emerging role of precision medicine in biliary tract cancers.

Bogenberger JM, DeLeon TT, Arora M, Ahn DH, Borad MJ.

NPJ Precis Oncol. 2018 Oct 3;2:21. doi: 10.1038/s41698-018-0064-z. eCollection 2018. Review.

10.

E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.

Babiker HM, Byron SA, Hendricks WPD, Elmquist WF, Gampa G, Vondrak J, Aldrich J, Cuyugan L, Adkins J, De Luca V, Tibes R, Borad MJ, Marceau K, Myers TJ, Paradiso LJ, Liang WS, Korn RL, Cridebring D, Von Hoff DD, Carpten JD, Craig DW, Trent JM, Gordon MS.

Invest New Drugs. 2019 Aug;37(4):636-645. doi: 10.1007/s10637-018-0668-8. Epub 2018 Sep 28.

PMID:
30264293
11.

Novel immunotherapy strategies for hepatobiliary cancers.

DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ.

Immunotherapy. 2018 Sep;10(12):1077-1091. doi: 10.2217/imt-2018-0024.

PMID:
30185133
12.

HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma.

Lamberti D, Cristinziano G, Porru M, Leonetti C, Egan JB, Shi CX, Buglioni S, Amoreo CA, Castellani L, Borad MJ, Alemà S, Anastasi S, Segatto O.

Hepatology. 2019 Jan;69(1):131-142. doi: 10.1002/hep.30127. Epub 2018 Dec 14. Erratum in: Hepatology. 2019 Feb;69(2):925.

PMID:
30067876
13.

Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples.

Vasmatzis G, Wang X, Smadbeck JB, Murphy SJ, Geiersbach KB, Johnson SH, Gaitatzes AG, Asmann YW, Kosari F, Borad MJ, Serie DJ, McLaughlin SA, Kachergus JM, Necela BM, Thompson EA.

BMC Cancer. 2018 Jul 13;18(1):738. doi: 10.1186/s12885-018-4594-0.

14.

Exploring the role of oncolytic viruses in hepatobiliary cancers.

Tenneti P, Borad MJ, Babiker HM.

Immunotherapy. 2018 Aug;10(11):971-986. doi: 10.2217/imt-2018-0048. Epub 2018 Jun 14.

PMID:
29900755
15.

Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study.

Tibes R, Borad MJ, Dutcus CE, Reyderman L, Feit K, Eisen A, Verbel DA, Von Hoff DD.

Br J Cancer. 2018 Jun;118(12):1580-1585. doi: 10.1038/s41416-018-0099-5. Epub 2018 Jun 5.

16.

Evaluation of pre-analytical factors affecting plasma DNA analysis.

Markus H, Contente-Cuomo T, Farooq M, Liang WS, Borad MJ, Sivakumar S, Gollins S, Tran NL, Dhruv HD, Berens ME, Bryce A, Sekulic A, Ribas A, Trent JM, LoRusso PM, Murtaza M.

Sci Rep. 2018 May 9;8(1):7375. doi: 10.1038/s41598-018-25810-0.

17.

Prevalent hepatitis B surface antigen among first-time blood donors in Gabon.

Eko Mba JM, Bisseye C, Ntsame Ndong JM, Mombo LE, Bengone C, Mouelet Migolet G, M'batchi B, Kosiorek HE, Butterfield RJ, Roberts LR, Borad MJ, Nagalo BM.

PLoS One. 2018 Apr 13;13(4):e0194285. doi: 10.1371/journal.pone.0194285. eCollection 2018.

18.

Oncolytic virotherapy in upper gastrointestinal tract cancers.

Yokoda R, Nagalo BM, Arora M, Egan JB, Bogenberger JM, DeLeon TT, Zhou Y, Ahn DH, Borad MJ.

Oncolytic Virother. 2018 Mar 23;7:13-24. doi: 10.2147/OV.S161397. eCollection 2017. Review.

19.

Oncolytic Adenoviruses in Gastrointestinal Cancers.

Yokoda RT, Nagalo BM, Borad MJ.

Biomedicines. 2018 Mar 11;6(1). pii: E33. doi: 10.3390/biomedicines6010033. Review.

20.

Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study).

Bergquist JR, Shah HN, Habermann EB, Hernandez MC, Ivanics T, Kendrick ML, Smoot RL, Nagorney DM, Borad MJ, McWilliams RR, Truty MJ.

Int J Surg. 2018 Apr;52:171-179. doi: 10.1016/j.ijsu.2018.02.052. Epub 2018 Feb 26.

PMID:
29496648
21.

Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.

DeLeon TT, Ahn DH, Bogenberger JM, Anastasiadis PZ, Arora M, Ramanathan RK, Aqel BA, Vasmatzis G, Truty MJ, Oklu R, Bekaii-Saab TS, Borad MJ.

Future Oncol. 2018 Mar;14(6):553-566. doi: 10.2217/fon-2017-0451. Epub 2018 Feb 20. Review.

PMID:
29460642
22.

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.

Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, Maneval DC, Jiang P, Shepard HM, Frost G, Von Hoff DD, Borad MJ, Ramanathan RK.

Br J Cancer. 2018 Jan;118(2):e3. doi: 10.1038/bjc.2017.438.

23.

Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis.

Ali AH, Tabibian JH, Nasser-Ghodsi N, Lennon RJ, DeLeon T, Borad MJ, Hilscher M, Silveira MG, Carey EJ, Lindor KD.

Hepatology. 2018 Jun;67(6):2338-2351. doi: 10.1002/hep.29730. Epub 2018 Apr 19.

PMID:
29244227
24.

Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.

Yokoda R, Nagalo BM, Vernon B, Oklu R, Albadawi H, DeLeon TT, Zhou Y, Egan JB, Duda DG, Borad MJ.

Oncolytic Virother. 2017 Nov 8;6:39-49. doi: 10.2147/OV.S145262. eCollection 2017. Review.

25.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T.

J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.

26.

Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer.

Borad MJ, LoRusso PM.

Mayo Clin Proc. 2017 Oct;92(10):1583-1591. doi: 10.1016/j.mayocp.2017.08.002. Review.

PMID:
28982488
27.

Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma.

Conroy M, Borad MJ, Bryce AH.

Cureus. 2017 Jul 26;9(7):e1517. doi: 10.7759/cureus.1517.

28.

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.

Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, Maneval DC, Jiang P, Shepard HM, Frost G, Von Hoff DD, Borad MJ, Ramanathan RK.

Br J Cancer. 2018 Jan;118(2):153-161. doi: 10.1038/bjc.2017.327. Epub 2017 Sep 26. Erratum in: Br J Cancer. 2018 Jan;118(2):e3.

29.

Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer.

Pershad Y, Govindan S, Hara AK, Borad MJ, Bekaii-Saab T, Wallace A, Albadawi H, Oklu R.

Diagnostics (Basel). 2017 Sep 2;7(3). pii: E50. doi: 10.3390/diagnostics7030050.

30.

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.

Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH, Bekaii-Saab T.

Cancer. 2017 Dec 1;123(23):4680-4686. doi: 10.1002/cncr.30927. Epub 2017 Aug 17.

31.

18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer.

Korn RL, Von Hoff DD, Borad MJ, Renschler MF, McGovern D, Curtis Bay R, Ramanathan RK.

Cancer Imaging. 2017 Aug 3;17(1):23. doi: 10.1186/s40644-017-0125-5.

32.

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.

Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ; Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN.

Cell Rep. 2017 Jun 27;19(13):2878-2880. doi: 10.1016/j.celrep.2017.06.008. No abstract available.

33.

Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.

Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, Chanan-Khan A, Patnaik MM, Ansell SM, Banck MS, Robinson SI, Mansfield AS, Klee EW, Oliver GR, McCormick JB, Huneke NE, Tagtow CM, Jenkins RB, Rumilla KM, Kerr SE, Kocher JA, Beck SA, Fernandez-Zapico ME, Farrugia G, Lazaridis KN, McWilliams RR.

Oncotarget. 2017 Apr 18;8(16):27145-27154. doi: 10.18632/oncotarget.16057.

34.

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.

Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ; Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN.

Cell Rep. 2017 Mar 14;18(11):2780-2794. doi: 10.1016/j.celrep.2017.02.033. Erratum in: Cell Rep. 2017 Jun 27;19(13):2878-2880.

35.

Immunotherapy in pancreatic cancer treatment: a new frontier.

Thind K, Padrnos LJ, Ramanathan RK, Borad MJ.

Therap Adv Gastroenterol. 2017 Jan;10(1):168-194. doi: 10.1177/1756283X16667909. Epub 2016 Oct 17. Review.

36.

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.

Babiker HM, Riaz IB, Husnain M, Borad MJ.

Oncolytic Virother. 2017 Feb 9;6:11-18. doi: 10.2147/OV.S100072. eCollection 2017. Review. Erratum in: Oncolytic Virother. 2019 Jan 04;8:1.

37.

Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib.

Bryce AH, Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, McCullough AE, Hunt KS, Ritacca NR, Barrett MT, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, Stanton ML, Cheville J, Swanson S, Schneider DE, McWilliams RR, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Von Hoff DD, Craig DW, Stewart AK, Carpten JD.

Clin Genitourin Cancer. 2017 Aug;15(4):e727-e734. doi: 10.1016/j.clgc.2016.11.001. Epub 2016 Dec 1. No abstract available.

38.

Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma.

Egan JB, Marks DL, Hogenson TL, Vrabel AM, Sigafoos AN, Tolosa EJ, Carr RM, Safgren SL, Hesles EE, Almada LL, Romecin-Duran PA, Iguchi E, Ala'Aldeen A, Kocher JA, Oliver GR, Prodduturi N, Mead DW, Hossain A, Huneke NE, Tagtow CM, Ailawadhi S, Ansell SM, Banck MS, Bryce AH, Carballido EM, Chanan-Khan AA, Curtis KK, Resnik E, Gawryletz CD, Go RS, Halfdanarson TR, Ho TH, Joseph RW, Kapoor P, Mansfield AS, Meurice N, Nageswara Rao AA, Nowakowski GS, Pardanani A, Parikh SA, Cheville JC, Feldman AL, Ramanathan RK, Robinson SI, Tibes R, Finnes HD, McCormick JB, McWilliams RR, Jatoi A, Patnaik MM, Silva AC, Wieben ED, McAllister TM, Rumilla KM, Kerr SE, Lazaridis KN, Farrugia G, Stewart AK, Clark KJ, Kennedy EJ, Klee EW, Borad MJ, Fernandez-Zapico ME.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00018. Epub 2017 Aug 1.

39.

Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers.

Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, Ritacca NR, McCullough AE, Barrett MT, Hunt KS, Champion MD, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, McWilliams RR, Lazaridis KN, Ramanathan RK, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Valdez R, Jaroszewski DE, Von Hoff DD, Craig DW, Stewart AK, Carpten JD, Bryce AH.

Sci Rep. 2016 Dec 23;6(1):25. doi: 10.1038/s41598-016-0021-4.

40.

Hepatoid Carcinoma of the Pancreas: Case Report, Next-Generation Tumor Profiling, and Literature Review.

Chang JM, Katariya NN, Lam-Himlin DM, Haakinson DJ, Ramanathan RK, Halfdanarson TR, Borad MJ, Pannala R, Faigel D, Moss AA, Mathur AK.

Case Rep Gastroenterol. 2016 Oct 18;10(3):605-612. eCollection 2016 Sep-Dec.

41.

The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?

Rizvi S, Borad MJ.

J Gastrointest Oncol. 2016 Oct;7(5):789-796. Review.

42.

Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma.

Babiker HM, Riaz IB, Shah SR, Von Hoff DD, Borad MJ.

Anticancer Drugs. 2017 Feb;28(2):127-132. doi: 10.1097/CAD.0000000000000437. Review.

PMID:
27685167
43.

Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.

Wang Y, Ding X, Wang S, Moser CD, Shaleh HM, Mohamed EA, Chaiteerakij R, Allotey LK, Chen G, Miyabe K, McNulty MS, Ndzengue A, Barr Fritcher EG, Knudson RA, Greipp PT, Clark KJ, Torbenson MS, Kipp BR, Zhou J, Barrett MT, Gustafson MP, Alberts SR, Borad MJ, Roberts LR.

Cancer Lett. 2016 Sep 28;380(1):163-73. doi: 10.1016/j.canlet.2016.05.017. Epub 2016 May 20.

44.

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.

Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, de Vries EG, Verheul HM, Lieu CH, Kim GP, Wang Y, Scales SJ, Samineni D, Brunstein F, Choi Y, Maslyar DJ, Colon-Otero G.

Mol Cancer Ther. 2016 Mar;15(3):439-47. doi: 10.1158/1535-7163.MCT-15-0693. Epub 2016 Jan 28.

45.

Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas.

Elquza E, Babiker HM, Howell KJ, Kovoor AI, Brown TD, Patel H, Malangone SA, Borad MJ, Dragovich T.

Cancer Invest. 2016;34(2):57-63. doi: 10.3109/07357907.2015.1108426. Epub 2016 Jan 25.

PMID:
26810581
46.

Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.

Hubbard JM, Kim G, Borad MJ, Johnson E, Qin R, Lensing J, Puttabasavaiah S, Wright J, Erlichman C, Grothey A.

Invest New Drugs. 2016 Feb;34(1):96-103. doi: 10.1007/s10637-015-0308-5. Epub 2015 Nov 18.

47.

Oncolytic viruses: perspectives on clinical development.

Burke J, Nieva J, Borad MJ, Breitbach CJ.

Curr Opin Virol. 2015 Aug;13:55-60. doi: 10.1016/j.coviro.2015.03.020. Epub 2015 May 16. Review.

PMID:
25989094
48.

A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphoma.

Borad MJ, Babiker HM, Anthony S, Mita M, Buchbinder A, Keilani T, Grem J.

Cancer Invest. 2015 May;33(5):172-9. doi: 10.3109/07357907.2015.1019677. Epub 2015 Apr 6.

PMID:
25844818
49.

Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.

Borad MJ, Gores GJ, Roberts LR.

Curr Opin Gastroenterol. 2015 May;31(3):264-8. doi: 10.1097/MOG.0000000000000171. Review.

50.

IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism.

Yamada D, Rizvi S, Razumilava N, Bronk SF, Davila JI, Champion MD, Borad MJ, Bezerra JA, Chen X, Gores GJ.

Hepatology. 2015 May;61(5):1627-42. doi: 10.1002/hep.27687. Epub 2015 Mar 20.

Supplemental Content

Loading ...
Support Center